An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment

Trial Profile

An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Carcinoid tumour; Meningioma; Neuroendocrine tumours; Pituitary cancer; Prostate cancer; Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Aug 2016 Planned number of patients changed from 220 to 400.
    • 07 Jan 2016 Planned End Date changed from 1 Apr 2023 to 1 Jul 2024 as reported by ClinicalTrials.gov record.
    • 07 Jan 2016 Planned primary completion date changed from 1 Apr 2023 to 1 Jul 2024 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top